Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Identifieur interne : 000889 ( PubMed/Checkpoint ); précédent : 000888; suivant : 000890Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Auteurs : Per-Henrik Groop [Finlande] ; Mark E. Cooper [Australie] ; Vlado Perkovic [Australie] ; Berthold Hocher [Allemagne] ; Keizo Kanasaki [Japon] ; Masakazu Haneda [Japon] ; Guntram Schernthaner [Autriche] ; Kumar Sharma [États-Unis] ; Robert C. Stanton [États-Unis] ; Robert Toto [États-Unis] ; Jessica Cescutti [France] ; Maud Gordat [France] ; Thomas Meinicke [Allemagne] ; Audrey Koitka-Weber [Allemagne] ; Sandra Thiemann [Allemagne] ; Maximilian Von Eynatten [Allemagne]Source :
- Diabetes, obesity & metabolism [ 1463-1326 ] ; 2017.
Abstract
The MARLINA-T2D study (ClinicalTrials.gov, NCT01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard-of-care in individuals with type 2 diabetes and albuminuria.
DOI: 10.1111/dom.13041
PubMed: 28636754
Affiliations:
- Allemagne, Australie, Autriche, Finlande, France, Japon, États-Unis
- Brandebourg, Californie, Champagne-Ardenne, Grand Est, Massachusetts, Nouvelle-Galles du Sud, Texas, Victoria (État), Vienne (Autriche)
- Melbourne, Potsdam, Reims, Sydney, Vienne (Autriche)
- Université de Potsdam, Université de Sydney
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28636754Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.</title><author><name sortKey="Groop, Per Henrik" sort="Groop, Per Henrik" uniqKey="Groop P" first="Per-Henrik" last="Groop">Per-Henrik Groop</name><affiliation wicri:level="1"><nlm:affiliation>Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki</wicri:regionArea><wicri:noRegion>Helsinki</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, Mark E" sort="Cooper, Mark E" uniqKey="Cooper M" first="Mark E" last="Cooper">Mark E. Cooper</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Perkovic, Vlado" sort="Perkovic, Vlado" uniqKey="Perkovic V" first="Vlado" last="Perkovic">Vlado Perkovic</name><affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, Faculty of Medicine, University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The George Institute for Global Health, Faculty of Medicine, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Hocher, Berthold" sort="Hocher, Berthold" uniqKey="Hocher B" first="Berthold" last="Hocher">Berthold Hocher</name><affiliation wicri:level="4"><nlm:affiliation>Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Nutritional Science, University of Potsdam, Potsdam</wicri:regionArea><placeName><region type="land" nuts="2">Brandebourg</region><settlement type="city">Potsdam</settlement><settlement type="city">Potsdam</settlement></placeName><orgName type="university">Université de Potsdam</orgName></affiliation></author><author><name sortKey="Kanasaki, Keizo" sort="Kanasaki, Keizo" uniqKey="Kanasaki K" first="Keizo" last="Kanasaki">Keizo Kanasaki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Diabetology and Endocrinology, Kanazawa Medical University, Kanazawa, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Diabetology and Endocrinology, Kanazawa Medical University, Kanazawa</wicri:regionArea><wicri:noRegion>Kanazawa</wicri:noRegion></affiliation></author><author><name sortKey="Haneda, Masakazu" sort="Haneda, Masakazu" uniqKey="Haneda M" first="Masakazu" last="Haneda">Masakazu Haneda</name><affiliation wicri:level="1"><nlm:affiliation>Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa</wicri:regionArea><wicri:noRegion>Asahikawa</wicri:noRegion></affiliation></author><author><name sortKey="Schernthaner, Guntram" sort="Schernthaner, Guntram" uniqKey="Schernthaner G" first="Guntram" last="Schernthaner">Guntram Schernthaner</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Rudolfstiftung Hospital, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Internal Medicine, Rudolfstiftung Hospital, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Sharma, Kumar" sort="Sharma, Kumar" uniqKey="Sharma K" first="Kumar" last="Sharma">Kumar Sharma</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Center for Renal Translational Medicine, University of California, San Diego, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Center for Renal Translational Medicine, University of California, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Stanton, Robert C" sort="Stanton, Robert C" uniqKey="Stanton R" first="Robert C" last="Stanton">Robert C. Stanton</name><affiliation wicri:level="2"><nlm:affiliation>Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Joslin Diabetes Center, Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Toto, Robert" sort="Toto, Robert" uniqKey="Toto R" first="Robert" last="Toto">Robert Toto</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas</wicri:cityArea></affiliation></author><author><name sortKey="Cescutti, Jessica" sort="Cescutti, Jessica" uniqKey="Cescutti J" first="Jessica" last="Cescutti">Jessica Cescutti</name><affiliation wicri:level="3"><nlm:affiliation>Boehringer Ingelheim France S.A.S, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Boehringer Ingelheim France S.A.S, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Gordat, Maud" sort="Gordat, Maud" uniqKey="Gordat M" first="Maud" last="Gordat">Maud Gordat</name><affiliation wicri:level="3"><nlm:affiliation>Boehringer Ingelheim France S.A.S, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Boehringer Ingelheim France S.A.S, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Meinicke, Thomas" sort="Meinicke, Thomas" uniqKey="Meinicke T" first="Thomas" last="Meinicke">Thomas Meinicke</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach</wicri:regionArea><wicri:noRegion>Biberach</wicri:noRegion><wicri:noRegion>Biberach</wicri:noRegion><wicri:noRegion>Biberach</wicri:noRegion></affiliation></author><author><name sortKey="Koitka Weber, Audrey" sort="Koitka Weber, Audrey" uniqKey="Koitka Weber A" first="Audrey" last="Koitka-Weber">Audrey Koitka-Weber</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach</wicri:regionArea><wicri:noRegion>Biberach</wicri:noRegion><wicri:noRegion>Biberach</wicri:noRegion><wicri:noRegion>Biberach</wicri:noRegion></affiliation></author><author><name sortKey="Thiemann, Sandra" sort="Thiemann, Sandra" uniqKey="Thiemann S" first="Sandra" last="Thiemann">Sandra Thiemann</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion></affiliation></author><author><name sortKey="Von Eynatten, Maximilian" sort="Von Eynatten, Maximilian" uniqKey="Von Eynatten M" first="Maximilian" last="Von Eynatten">Maximilian Von Eynatten</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28636754</idno><idno type="pmid">28636754</idno><idno type="doi">10.1111/dom.13041</idno><idno type="wicri:Area/PubMed/Corpus">000108</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000108</idno><idno type="wicri:Area/PubMed/Curation">000108</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000108</idno><idno type="wicri:Area/PubMed/Checkpoint">000108</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000108</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.</title><author><name sortKey="Groop, Per Henrik" sort="Groop, Per Henrik" uniqKey="Groop P" first="Per-Henrik" last="Groop">Per-Henrik Groop</name><affiliation wicri:level="1"><nlm:affiliation>Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki</wicri:regionArea><wicri:noRegion>Helsinki</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, Mark E" sort="Cooper, Mark E" uniqKey="Cooper M" first="Mark E" last="Cooper">Mark E. Cooper</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Perkovic, Vlado" sort="Perkovic, Vlado" uniqKey="Perkovic V" first="Vlado" last="Perkovic">Vlado Perkovic</name><affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, Faculty of Medicine, University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The George Institute for Global Health, Faculty of Medicine, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Hocher, Berthold" sort="Hocher, Berthold" uniqKey="Hocher B" first="Berthold" last="Hocher">Berthold Hocher</name><affiliation wicri:level="4"><nlm:affiliation>Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Nutritional Science, University of Potsdam, Potsdam</wicri:regionArea><placeName><region type="land" nuts="2">Brandebourg</region><settlement type="city">Potsdam</settlement><settlement type="city">Potsdam</settlement></placeName><orgName type="university">Université de Potsdam</orgName></affiliation></author><author><name sortKey="Kanasaki, Keizo" sort="Kanasaki, Keizo" uniqKey="Kanasaki K" first="Keizo" last="Kanasaki">Keizo Kanasaki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Diabetology and Endocrinology, Kanazawa Medical University, Kanazawa, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Diabetology and Endocrinology, Kanazawa Medical University, Kanazawa</wicri:regionArea><wicri:noRegion>Kanazawa</wicri:noRegion></affiliation></author><author><name sortKey="Haneda, Masakazu" sort="Haneda, Masakazu" uniqKey="Haneda M" first="Masakazu" last="Haneda">Masakazu Haneda</name><affiliation wicri:level="1"><nlm:affiliation>Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa</wicri:regionArea><wicri:noRegion>Asahikawa</wicri:noRegion></affiliation></author><author><name sortKey="Schernthaner, Guntram" sort="Schernthaner, Guntram" uniqKey="Schernthaner G" first="Guntram" last="Schernthaner">Guntram Schernthaner</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Rudolfstiftung Hospital, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Internal Medicine, Rudolfstiftung Hospital, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Sharma, Kumar" sort="Sharma, Kumar" uniqKey="Sharma K" first="Kumar" last="Sharma">Kumar Sharma</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Center for Renal Translational Medicine, University of California, San Diego, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Center for Renal Translational Medicine, University of California, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Stanton, Robert C" sort="Stanton, Robert C" uniqKey="Stanton R" first="Robert C" last="Stanton">Robert C. Stanton</name><affiliation wicri:level="2"><nlm:affiliation>Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Joslin Diabetes Center, Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Toto, Robert" sort="Toto, Robert" uniqKey="Toto R" first="Robert" last="Toto">Robert Toto</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas</wicri:cityArea></affiliation></author><author><name sortKey="Cescutti, Jessica" sort="Cescutti, Jessica" uniqKey="Cescutti J" first="Jessica" last="Cescutti">Jessica Cescutti</name><affiliation wicri:level="3"><nlm:affiliation>Boehringer Ingelheim France S.A.S, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Boehringer Ingelheim France S.A.S, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Gordat, Maud" sort="Gordat, Maud" uniqKey="Gordat M" first="Maud" last="Gordat">Maud Gordat</name><affiliation wicri:level="3"><nlm:affiliation>Boehringer Ingelheim France S.A.S, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Boehringer Ingelheim France S.A.S, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Meinicke, Thomas" sort="Meinicke, Thomas" uniqKey="Meinicke T" first="Thomas" last="Meinicke">Thomas Meinicke</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach</wicri:regionArea><wicri:noRegion>Biberach</wicri:noRegion><wicri:noRegion>Biberach</wicri:noRegion><wicri:noRegion>Biberach</wicri:noRegion></affiliation></author><author><name sortKey="Koitka Weber, Audrey" sort="Koitka Weber, Audrey" uniqKey="Koitka Weber A" first="Audrey" last="Koitka-Weber">Audrey Koitka-Weber</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach</wicri:regionArea><wicri:noRegion>Biberach</wicri:noRegion><wicri:noRegion>Biberach</wicri:noRegion><wicri:noRegion>Biberach</wicri:noRegion></affiliation></author><author><name sortKey="Thiemann, Sandra" sort="Thiemann, Sandra" uniqKey="Thiemann S" first="Sandra" last="Thiemann">Sandra Thiemann</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion></affiliation></author><author><name sortKey="Von Eynatten, Maximilian" sort="Von Eynatten, Maximilian" uniqKey="Von Eynatten M" first="Maximilian" last="Von Eynatten">Maximilian Von Eynatten</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim</wicri:regionArea><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion></affiliation></author></analytic><series><title level="j">Diabetes, obesity & metabolism</title><idno type="eISSN">1463-1326</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The MARLINA-T2D study (ClinicalTrials.gov, NCT01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard-of-care in individuals with type 2 diabetes and albuminuria.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28636754</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>21</Day></DateCreated><DateRevised><Year>2017</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1463-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Diabetes, obesity & metabolism</Title><ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation></Journal><ArticleTitle>Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.</ArticleTitle><Pagination><MedlinePgn>1610-1619</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.13041</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The MARLINA-T2D study (ClinicalTrials.gov, NCT01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard-of-care in individuals with type 2 diabetes and albuminuria.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 360 individuals with type 2 diabetes, HbA1c 6.5% to 10.0% (48-86 mmol/mol), estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m(2) and urinary albumin-to-creatinine ratio (UACR) 30-3000 mg/g despite single agent renin-angiotensin-system blockade were randomized to double-blind linagliptin (n = 182) or placebo (n = 178) for 24 weeks. The primary and key secondary endpoints were change from baseline in HbA1c at week 24 and time-weighted average of percentage change from baseline in UACR over 24 weeks, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline mean HbA1c and geometric mean (gMean) UACR were 7.8% ± 0.9% (62.2 ± 9.6 mmol/mol) and 126 mg/g, respectively; 73.7% and 20.3% of participants had microalbuminuria or macroalbuminuria, respectively. After 24 weeks, the placebo-adjusted mean change in HbA1c from baseline was -0.60% (-6.6 mmol/mol) (95% confidence interval [CI], -0.78 to -0.43 [-8.5 to -4.7 mmol/mol]; P < .0001). The placebo-adjusted gMean for time-weighted average of percentage change in UACR from baseline was -6.0% (95% CI, -15.0 to 3.0; P = .1954). The adverse-event profile, including renal safety and change in eGFR, was similar between the linagliptin and placebo groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In individuals at early stages of diabetic kidney disease, linagliptin significantly improved glycaemic control but did not significantly lower albuminuria. There was no significant change in placebo-adjusted eGFR. Detection of clinically relevant renal effects of linagliptin may require longer treatment, as its main experimental effects in animal studies have been to reduce interstitial fibrosis rather than alter glomerular haemodynamics.</AbstractText><CopyrightInformation>© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Groop</LastName><ForeName>Per-Henrik</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkovic</LastName><ForeName>Vlado</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health, Faculty of Medicine, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hocher</LastName><ForeName>Berthold</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Histology and Embryology, Medical College, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IFLb, Institut für Laboratoriumsmedizin Berlin GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanasaki</LastName><ForeName>Keizo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Diabetology and Endocrinology, Kanazawa Medical University, Kanazawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haneda</LastName><ForeName>Masakazu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schernthaner</LastName><ForeName>Guntram</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rudolfstiftung Hospital, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Kumar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Center for Renal Translational Medicine, University of California, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toto</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cescutti</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim France S.A.S, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordat</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim France S.A.S, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meinicke</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koitka-Weber</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiemann</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Eynatten</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabetes Obes Metab</MedlineTA><NlmUniqueID>100883645</NlmUniqueID><ISSNLinking>1462-8902</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Regul Pept. 2007 Jun 7;141(1-3):120-8</RefSource><PMID Version="1">17276524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2015 Jan;38(1):140-9</RefSource><PMID Version="1">25538310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Jul 28;375(4):311-22</RefSource><PMID Version="1">27295427</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Kidney Dis. 2015 Sep;66(3):441-9</RefSource><PMID Version="1">25960304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Horm Metab Res. 2014 Sep;46(10):717-21</RefSource><PMID Version="1">24710699</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Regul Pept. 1999 Nov 30;85(1):9-24</RefSource><PMID Version="1">10588446</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2015 Sep;88(3):479-89</RefSource><PMID Version="1">25830763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2013 Feb;24(2):302-8</RefSource><PMID Version="1">23362314</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Kidney Dis. 2012 Nov;60(5):850-86</RefSource><PMID Version="1">23067652</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diab Vasc Dis Res. 2015 Nov;12(6):455-62</RefSource><PMID Version="1">26224765</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2013 Feb;36(2):237-44</RefSource><PMID Version="1">23033241</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2015 Aug;26(8):2055-64</RefSource><PMID Version="1">25421558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2017 Jan;28(1):368-375</RefSource><PMID Version="1">27539604</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2011 Jun;79(12):1341-52</RefSource><PMID Version="1">21307840</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2016 Feb;101(2):748-56</RefSource><PMID Version="1">26695864</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Nov 10;380(9854):1662-73</RefSource><PMID Version="1">23013602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2016 May;89(5):1049-1061</RefSource><PMID Version="1">27083282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Nov 10;375(19):1834-1844</RefSource><PMID Version="1">27633186</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2011 Jun;32(12 ):1493-9</RefSource><PMID Version="1">21421598</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2016 Sep;59(9):1860-70</RefSource><PMID Version="1">27316632</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2007 May;18(5):1540-6</RefSource><PMID Version="1">17409317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2016 Oct;90(4):783-96</RefSource><PMID Version="1">27475229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2004 Jun;65(6):2309-20</RefSource><PMID Version="1">15149345</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2013 Nov;36(11):3460-8</RefSource><PMID Version="1">24026560</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hypertens. 2014 Nov;32(11):2211-23; discussion 2223</RefSource><PMID Version="1">25215436</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Histochem. 1991;91(1):105-9</RefSource><PMID Version="1">1686953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Diabetol. 2013 Aug 28;12:125</RefSource><PMID Version="1">23984879</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2009 Nov;31(11):2608-17</RefSource><PMID Version="1">20110005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2017 Jan;40(1):69-76</RefSource><PMID Version="1">27797925</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hypertens. 2013 Nov;31(11):2290-8; discussion 2299</RefSource><PMID Version="1">24077249</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2008 May;51(5):714-25</RefSource><PMID Version="1">18347777</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2009 Aug;20(8):1813-21</RefSource><PMID Version="1">19443635</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2014 Jun;63(6):2120-31</RefSource><PMID Version="1">24574044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2015 Feb;38(2):e15-7</RefSource><PMID Version="1">25614693</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Obesity (Silver Spring). 2014 Oct;22(10):2172-9</RefSource><PMID Version="1">24995775</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2016 Oct;65(10 ):2966-79</RefSource><PMID Version="1">27445264</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2004 Aug 24;110(8):921-7</RefSource><PMID Version="1">15302780</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Obes Metab. 2016 Jun;18(6):590-7</RefSource><PMID Version="1">26936519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2011 Jun 22;305(24):2532-9</RefSource><PMID Version="1">21693741</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Diabetes Endocrinol. 2016 Aug;4(8):638-40</RefSource><PMID Version="1">27160545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Oct 28;10(10):e0141143</RefSource><PMID Version="1">26509887</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Obes Metab. 2017 Nov;19(11):1610-1619</RefSource><PMID Version="1">28636754</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DPP-IV inhibitor</Keyword><Keyword MajorTopicYN="N">antidiabetic drug</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">diabetic nephropathy</Keyword><Keyword MajorTopicYN="N">glycaemic control</Keyword><Keyword MajorTopicYN="N">linagliptin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28636754</ArticleId><ArticleId IdType="doi">10.1111/dom.13041</ArticleId><ArticleId IdType="pmc">PMC5655723</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Finlande</li><li>France</li><li>Japon</li><li>États-Unis</li></country><region><li>Brandebourg</li><li>Californie</li><li>Champagne-Ardenne</li><li>Grand Est</li><li>Massachusetts</li><li>Nouvelle-Galles du Sud</li><li>Texas</li><li>Victoria (État)</li><li>Vienne (Autriche)</li></region><settlement><li>Melbourne</li><li>Potsdam</li><li>Reims</li><li>Sydney</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Potsdam</li><li>Université de Sydney</li></orgName></list><tree><country name="Finlande"><noRegion><name sortKey="Groop, Per Henrik" sort="Groop, Per Henrik" uniqKey="Groop P" first="Per-Henrik" last="Groop">Per-Henrik Groop</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Cooper, Mark E" sort="Cooper, Mark E" uniqKey="Cooper M" first="Mark E" last="Cooper">Mark E. Cooper</name></region><name sortKey="Perkovic, Vlado" sort="Perkovic, Vlado" uniqKey="Perkovic V" first="Vlado" last="Perkovic">Vlado Perkovic</name></country><country name="Allemagne"><region name="Brandebourg"><name sortKey="Hocher, Berthold" sort="Hocher, Berthold" uniqKey="Hocher B" first="Berthold" last="Hocher">Berthold Hocher</name></region><name sortKey="Koitka Weber, Audrey" sort="Koitka Weber, Audrey" uniqKey="Koitka Weber A" first="Audrey" last="Koitka-Weber">Audrey Koitka-Weber</name><name sortKey="Meinicke, Thomas" sort="Meinicke, Thomas" uniqKey="Meinicke T" first="Thomas" last="Meinicke">Thomas Meinicke</name><name sortKey="Thiemann, Sandra" sort="Thiemann, Sandra" uniqKey="Thiemann S" first="Sandra" last="Thiemann">Sandra Thiemann</name><name sortKey="Von Eynatten, Maximilian" sort="Von Eynatten, Maximilian" uniqKey="Von Eynatten M" first="Maximilian" last="Von Eynatten">Maximilian Von Eynatten</name></country><country name="Japon"><noRegion><name sortKey="Kanasaki, Keizo" sort="Kanasaki, Keizo" uniqKey="Kanasaki K" first="Keizo" last="Kanasaki">Keizo Kanasaki</name></noRegion><name sortKey="Haneda, Masakazu" sort="Haneda, Masakazu" uniqKey="Haneda M" first="Masakazu" last="Haneda">Masakazu Haneda</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Schernthaner, Guntram" sort="Schernthaner, Guntram" uniqKey="Schernthaner G" first="Guntram" last="Schernthaner">Guntram Schernthaner</name></region></country><country name="États-Unis"><region name="Californie"><name sortKey="Sharma, Kumar" sort="Sharma, Kumar" uniqKey="Sharma K" first="Kumar" last="Sharma">Kumar Sharma</name></region><name sortKey="Stanton, Robert C" sort="Stanton, Robert C" uniqKey="Stanton R" first="Robert C" last="Stanton">Robert C. Stanton</name><name sortKey="Toto, Robert" sort="Toto, Robert" uniqKey="Toto R" first="Robert" last="Toto">Robert Toto</name></country><country name="France"><region name="Grand Est"><name sortKey="Cescutti, Jessica" sort="Cescutti, Jessica" uniqKey="Cescutti J" first="Jessica" last="Cescutti">Jessica Cescutti</name></region><name sortKey="Gordat, Maud" sort="Gordat, Maud" uniqKey="Gordat M" first="Maud" last="Gordat">Maud Gordat</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000889 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000889 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28636754
|texte= Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28636754" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |